Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Alnylam Pharmaceuticals Inc's Business Segments
Alnylam Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
19
Largest Segment
Net product revenues
Total Revenue
$ 1,167
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Net product revenues88.8%
- Total TTR78%
- AMVUTTRA76.2%
- Total Rare10.8%
- Net revenues from collaborations7%
- GIVLAARI6.4%
- OXLUMO4.4%
- Net revenues from collaborations Regeneron Pharmaceuticals4%
- Regeneron Pharmaceuticals4%
- Global Strategic Collaboration Regeneron Pharmaceuticals Other license programs3.4%
- Regeneron Pharmaceuticals Other license programs Global Strategic Collaboration3.4%
- Net revenues from collaborations Roche3.1%
- Roche Roche Collaboration and License Agreement3.1%
- Roche Roche Development Services Obligation Roche Collaboration and License Agreement2.9%
- ONPATTRO1.8%
- Global Strategic Collaboration Regeneron Pharmaceuticals Research Services Obligation0.6%
- Regeneron Pharmaceuticals Research Services Obligation Global Strategic Collaboration0.6%
- Roche Other Roche Collaboration and License Agreement0.1%
- Net revenues from collaborations Other0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Net product revenues | $ 1,036 | 88.8% |
| Total TTR | $ 910 | 78% |
| AMVUTTRA | $ 890 | 76.2% |
16 more segments available
Sign in to unlock the full Alnylam Pharmaceuticals Inc dataset.
Revenue by Product & Service Category - FY
- Product88.8%
- TTR78%
- AMVUTTRA60.2%
- Rare10.8%
- Collaborations7%
- GIVLAARI4.2%
- Royalty4.2%
- Other License Programs3.4%
- Development Services Obligation2.9%
- OXLUMO1.5%
- ONPATTRO0.9%
- Research Services Obligation0.6%
- Product and Service, Other0.1%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 1,036 | 88.8% |
| TTR | $ 910 | 78% |
| AMVUTTRA | $ 703 | 60.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
10 more categories available
Sign in to unlock the full Alnylam Pharmaceuticals Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Net product revenues88.8%
- Total TTR78%
- AMVUTTRA76.2%
- Total Rare10.8%
- Net revenues from collaborations7%
- GIVLAARI6.4%
- OXLUMO4.4%
- Net revenues from collaborations Regeneron Pharmaceuticals4%
- Regeneron Pharmaceuticals4%
- Global Strategic Collaboration Regeneron Pharmaceuticals Other license programs3.4%
- Regeneron Pharmaceuticals Other license programs Global Strategic Collaboration3.4%
- Net revenues from collaborations Roche3.1%
- Roche Roche Collaboration and License Agreement3.1%
- Roche Roche Development Services Obligation Roche Collaboration and License Agreement2.9%
- ONPATTRO1.8%
- Global Strategic Collaboration Regeneron Pharmaceuticals Research Services Obligation0.6%
- Regeneron Pharmaceuticals Research Services Obligation Global Strategic Collaboration0.6%
- Roche Other Roche Collaboration and License Agreement0.1%
- Net revenues from collaborations Other0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Net product revenues | $ 1,036 | 88.8% |
| Total TTR | $ 910 | 78% |
| AMVUTTRA | $ 890 | 76.2% |
16 more segments available
Sign in to unlock the full Alnylam Pharmaceuticals Inc dataset.
Description of Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc. is a biotechnology company that specializes in the development of RNA interference (RNAi) therapeutics. RNAi is a natural cellular process that controls the expression of genes, and Alnylam's approach is to use this process to treat various diseases. The company's platform allows for the specific silencing of disease-causing genes, preventing them from producing proteins that cause harm.
Alnylam was founded in 2002 and is based in Cambridge, MA. The company has a strong pipeline of RNAi therapeutic programs, with a focus on genetic diseases, liver diseases, and central nervous system (CNS) disorders. Its lead program is Givlaari (givosiran), a treatment for acute hepatic porphyria (AHP), a rare and life-threatening genetic disease.
Alnylam's pipeline also includes a treatment for hemophilia A and B, a rare genetic bleeding disorder, and a treatment for ATTR amyloidosis, a condition that causes a buildup of abnormal proteins in the body's organs and tissues. The company has several other preclinical and clinical programs in development for a broad range of diseases.
Alnylam has partnered with several pharmaceutical companies, including Sanofi and Regeneron, to develop RNAi therapeutics. The company has also established collaborations with academic institutions and research organizations to advance its platform and expand its pipeline.
Alnylam has a strong financial position, with a market capitalization of over $18 billion as of June 202 The company has reported positive financial results in recent quarters, with revenue increasing year over year. Alnylam also received approval for its first RNAi therapeutic, Onpattro (patisiran), in 2018, marking a significant milestone in the company's history.
Overall, Alnylam Pharmaceuticals Inc. is a leading biotechnology company in the RNAi therapeutics space, with a strong pipeline and a focus on developing treatments for rare diseases. The company's innovative approach to gene silencing has the potential to offer significant benefits to patients with a range of conditions.
Alnylam was founded in 2002 and is based in Cambridge, MA. The company has a strong pipeline of RNAi therapeutic programs, with a focus on genetic diseases, liver diseases, and central nervous system (CNS) disorders. Its lead program is Givlaari (givosiran), a treatment for acute hepatic porphyria (AHP), a rare and life-threatening genetic disease.
Alnylam's pipeline also includes a treatment for hemophilia A and B, a rare genetic bleeding disorder, and a treatment for ATTR amyloidosis, a condition that causes a buildup of abnormal proteins in the body's organs and tissues. The company has several other preclinical and clinical programs in development for a broad range of diseases.
Alnylam has partnered with several pharmaceutical companies, including Sanofi and Regeneron, to develop RNAi therapeutics. The company has also established collaborations with academic institutions and research organizations to advance its platform and expand its pipeline.
Alnylam has a strong financial position, with a market capitalization of over $18 billion as of June 202 The company has reported positive financial results in recent quarters, with revenue increasing year over year. Alnylam also received approval for its first RNAi therapeutic, Onpattro (patisiran), in 2018, marking a significant milestone in the company's history.
Overall, Alnylam Pharmaceuticals Inc. is a leading biotechnology company in the RNAi therapeutics space, with a strong pipeline and a focus on developing treatments for rare diseases. The company's innovative approach to gene silencing has the potential to offer significant benefits to patients with a range of conditions.
Alnylam Pharmaceuticals Inc. is a pioneering biopharmaceutical company that focuses on the development of RNA interference (RNAi) therapeutics aimed at treating a range of diseases, particularly those with genetic components. With a commitment to leveraging RNAi technology, Alnylam has made significant strides in pharmacological research, moving from discovery to clinical application, and commercial deployment of its products. Below, an extensive description of the companys segments, products, and services is provided.
Segments
1. RNAi Therapeutics:
This core segment is dedicated to advancing RNAi as a transformative platform for the treatment of various diseases. The development pipeline includes therapies targeting a wide spectrum of conditions such as genetic disorders, metabolic diseases, and cardiovascular diseases. The intent is not only to address prevalent diseases but also to innovate therapeutics for rare diseases that lack effective treatments.
2. Alnylam 5x15:
This strategic initiative aims to develop and commercialize five RNAi therapeutics for rare genetic diseases by 2015. The program signifies Alnylam’s commitment to addressing unmet medical needs, focusing on diseases that typically have limited therapeutic options due to their rarity and complexity. The project encapsulates Alnylams vision to harness RNAi for a diverse range of genetic conditions effectively.
3. Expanded Therapeutic Areas:
Beyond the core focus on genetic diseases, Alnylam is broadening its pipeline to potentially include applications in other therapeutic areas such as cardiometabolic diseases, infectious diseases, and more. This diversification enhances the utility of RNAi technology and increases the potential impact on global health.
Products
1. ONPATTRO (patisiran):
This was the first FDA-approved RNAi therapeutic and is designed to treat polyneuropathy stemming from hereditary transthyretin-mediated (hATTR) amyloidosis in adults. ONPATTRO works by silencing the gene responsible for producing the transthyretin protein, thereby reducing its concentrations and preventing the formation of toxic amyloid deposits that can severely damage nerves and organs.
2. GIVLAARI (givosiran):
GIVLAARI is targeted for the treatment of patients with acute hepatic porphyria (AHP). It acts by inhibiting the production of aminolevulinic acid synthase 1 (ALAS1), an enzyme that, when overproduced, leads to toxic heme intermediates that precipitate acute attacks. By lowering the levels of these intermediates, GIVLAARI helps reduce the frequency and severity of AHP attacks.
3. LUMASIRAN (Oxlumo):
LUMASIRAN addresses primary hyperoxaluria type 1 (PH1) by targeting hydroxypyruvate reductase (HPRT). This innovative therapy significantly diminishes oxalate production, mitigating the risk of kidney damage and related complications that arise due to oxalate accumulation in patients. The approval of LUMASIRAN has provided a critical breakthrough for individuals afflicted with PH1, fostering better management of this condition.
4. SILENCE (previously known as ALNYLAM-XYZ):
While specific details may still be evolving, the companys pipeline reportedly includes additional therapies in various stages of clinical development for multiple conditions. This underscores Alnylams robust commitment to expanding its portfolio of RNAi therapeutics to target more diseases effectively.
Services
1. Genetic Testing:
Alnylam provides genetic testing services that facilitate the identification of individuals at risk for hereditary diseases like hATTR amyloidosis, AHP, and PH1. The implementation of genetic screening is vital for early diagnosis and timely intervention, which can be transformative for patients’ health outcomes.
2. Patient Support Programs:
Understanding the complexities faced by patients with rare diseases, Alnylam offers a variety of support services. These include financial assistance options, educational resources tailored to help patients and their families understand their conditions and the treatments available, as well as access to specialized nursing staff who can provide guidance throughout the treatment journey.
3. Clinical Trials:
Alnylam is heavily invested in clinical research, consistently conducting trials to evaluate the safety and efficacy of its RNAi therapeutics. These trials not only advance the companys product pipeline but also provide patients with access to cutting-edge therapies and a chance to contribute to clinical advancements that can potentially aid future patients.
Conclusion
In summary, Alnylam Pharmaceuticals Inc. stands at the forefront of RNAi therapeutic development, offering innovative solutions to treat complex genetic diseases. Through its various segments focused on RNAi therapeutics, alongside a diverse array of products and supportive services, Alnylam seeks to change the treatment paradigm for patients worldwide. The companys ongoing research initiatives and commitment to patient care signify its dedication to addressing critical health needs and enhancing the quality of life for those with rare genetic conditions.
Segments
1. RNAi Therapeutics:
This core segment is dedicated to advancing RNAi as a transformative platform for the treatment of various diseases. The development pipeline includes therapies targeting a wide spectrum of conditions such as genetic disorders, metabolic diseases, and cardiovascular diseases. The intent is not only to address prevalent diseases but also to innovate therapeutics for rare diseases that lack effective treatments.
2. Alnylam 5x15:
This strategic initiative aims to develop and commercialize five RNAi therapeutics for rare genetic diseases by 2015. The program signifies Alnylam’s commitment to addressing unmet medical needs, focusing on diseases that typically have limited therapeutic options due to their rarity and complexity. The project encapsulates Alnylams vision to harness RNAi for a diverse range of genetic conditions effectively.
3. Expanded Therapeutic Areas:
Beyond the core focus on genetic diseases, Alnylam is broadening its pipeline to potentially include applications in other therapeutic areas such as cardiometabolic diseases, infectious diseases, and more. This diversification enhances the utility of RNAi technology and increases the potential impact on global health.
Products
1. ONPATTRO (patisiran):
This was the first FDA-approved RNAi therapeutic and is designed to treat polyneuropathy stemming from hereditary transthyretin-mediated (hATTR) amyloidosis in adults. ONPATTRO works by silencing the gene responsible for producing the transthyretin protein, thereby reducing its concentrations and preventing the formation of toxic amyloid deposits that can severely damage nerves and organs.
2. GIVLAARI (givosiran):
GIVLAARI is targeted for the treatment of patients with acute hepatic porphyria (AHP). It acts by inhibiting the production of aminolevulinic acid synthase 1 (ALAS1), an enzyme that, when overproduced, leads to toxic heme intermediates that precipitate acute attacks. By lowering the levels of these intermediates, GIVLAARI helps reduce the frequency and severity of AHP attacks.
3. LUMASIRAN (Oxlumo):
LUMASIRAN addresses primary hyperoxaluria type 1 (PH1) by targeting hydroxypyruvate reductase (HPRT). This innovative therapy significantly diminishes oxalate production, mitigating the risk of kidney damage and related complications that arise due to oxalate accumulation in patients. The approval of LUMASIRAN has provided a critical breakthrough for individuals afflicted with PH1, fostering better management of this condition.
4. SILENCE (previously known as ALNYLAM-XYZ):
While specific details may still be evolving, the companys pipeline reportedly includes additional therapies in various stages of clinical development for multiple conditions. This underscores Alnylams robust commitment to expanding its portfolio of RNAi therapeutics to target more diseases effectively.
Services
1. Genetic Testing:
Alnylam provides genetic testing services that facilitate the identification of individuals at risk for hereditary diseases like hATTR amyloidosis, AHP, and PH1. The implementation of genetic screening is vital for early diagnosis and timely intervention, which can be transformative for patients’ health outcomes.
2. Patient Support Programs:
Understanding the complexities faced by patients with rare diseases, Alnylam offers a variety of support services. These include financial assistance options, educational resources tailored to help patients and their families understand their conditions and the treatments available, as well as access to specialized nursing staff who can provide guidance throughout the treatment journey.
3. Clinical Trials:
Alnylam is heavily invested in clinical research, consistently conducting trials to evaluate the safety and efficacy of its RNAi therapeutics. These trials not only advance the companys product pipeline but also provide patients with access to cutting-edge therapies and a chance to contribute to clinical advancements that can potentially aid future patients.
Conclusion
In summary, Alnylam Pharmaceuticals Inc. stands at the forefront of RNAi therapeutic development, offering innovative solutions to treat complex genetic diseases. Through its various segments focused on RNAi therapeutics, alongside a diverse array of products and supportive services, Alnylam seeks to change the treatment paradigm for patients worldwide. The companys ongoing research initiatives and commitment to patient care signify its dedication to addressing critical health needs and enhancing the quality of life for those with rare genetic conditions.